Support for Continuing Work Sample Clauses
The "Support for Continuing Work" clause ensures that necessary resources, information, or assistance are provided to enable ongoing progress on a project or contract. In practice, this clause may require one party to supply timely approvals, access to facilities, or technical data so that the other party can continue their work without interruption. Its core function is to prevent delays and disruptions by clearly assigning responsibility for support, thereby facilitating smooth project execution.
POPULAR SAMPLE Copied 1 times
Support for Continuing Work. In consideration of IDRI’s continuing work described in Section 4.1, Immune Design shall pay IDRI non-creditable support fees as follows: (i) *** dollars ($***), payable within *** days after the Restated Effective Date; (ii) an additional *** dollars ($***) payable on or before ***; and (iii) an additional *** dollars ($***) payable on or before ***; provided, however, that if IDRI notifies Immune Design prior to any such payment due date(s) that IDRI will terminate the Continuing Work Period prior to ***, that payment (or those payments) will not become due from Immune Design and IDRI shall refund a pro-rata portion of the support payment received for the then-current *** period. The payments in this subsection (b) shall be used in support of IDRI’s research and development programs in the area of *** and/or modifications or other improvements to GLA (other than IDRI FMC Technology). Immune Design may terminate its payment obligations under this Section 6.1(b) effective upon *** by giving IDRI notice at least *** days before the effective date of termination. If IDRI terminates its payment obligations pursuant to the preceding sentence, no further payments shall be due under this clause (b) including any payment accruing on the effective date of termination. If Immune Design terminates its payment obligations under this clause (b), IDRI may terminate its continuing work effective on the effective date of such termination and Immune Design shall no longer have a first right of negotiation under Section 4.3.